Roth Capital Bullish on Recent BioBlast Pharma (ORPN) Hires; Reaffirms at 'Buy'
Get Alerts ORPN Hot Sheet
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Roth Capital reaffirms BioBlast Pharma (Nasdaq: ORPN) with a Buy rating and $26 price target after ORPN announced the appointment of three new senior executives to its leadership team: Warren Wasiewski, M.D. as Chief Medical Officer and Vice President, Research & Development, Leigh Cherry as Vice President Manufacturing, and Stacey Jurchison as Vice President, Investor Relations & Corporate Communications. Recently, the company also announced the appointments of Paul Firuta as Chief Commercial Officer, and Theresa (Terri) Stevens as Chief Corporate Development Officer. All are U.S.-based positions with global responsibilities.
Analyst Joseph Pantginis commented on recent hires: We emphasize these hires as 1) support for our thesis anticipating rapid development of the orphan pipeline, 2) the company's full transition to development and commercialization phase and 3) establishment of the U.S. HQ footprint.
For an analyst ratings summary and ratings history on Bio Blast Pharma click here. For more ratings news on Bio Blast Pharma click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Upgrades Citizen Watch (7762:JP) to Buy
- Cantor Fitzgerald Downgrades Caledonia Mining Corporation (CMCL) to Hold
- Bank of America (BAC) PT Raised to $44 at Wells Fargo
Create E-mail Alert Related Categories
Analyst Comments, Management ChangesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!